Dalbavancin (INN, trade names Dalvance in the US and Xydalba in Europe) is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA)
| Product Name: | Dalbavancin |
| Synonyms: | Dalbavancin;CS-2250;Dalbavancin Ao;Dalbavancin(BI 397;DALBAVANCIN;MDL 63397;A-A-1; DALBAVANCIN AO; BI 397; MDL 63397;DALBAVANCIN(BI 397; MDL 63397);Dalbavacin;Antibotic Dalbavancin;DB/ QTH04 |
| CAS: | 171500-79-1 |
| MF: | C88H100Cl2N10O28 |
| MW: | 1816.71 |